Login Register Cart 0
Generic placeholder image

Combinatorial Chemistry & High Throughput Screening

Editor-in-Chief

ISSN (Print): 1386-2073
ISSN (Online): 1875-5402

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Neobavaisoflavone Demonstrates Valid Anti-tumor Effects in Non-Small- Cell Lung Cancer by Inhibiting STAT3

Author(s): Xueding Cai, Feng Zhou, Xiaona Xie, Dandan Zheng, Yulei Yao, Chengguang Zhao*, Xiaoying Huang* and Ke Hu*

Volume 25, Issue 1, 2022

Published on: 04 December, 2020

Page: [29 - 37] Pages: 9

DOI: 10.2174/1386207323666201204135941

Price: $65

Abstract

Aim and Objective: Lung cancer is the most commonly occurring cancer, which contributes to the majority of death caused by cancer, where non-small-cell lung cancer (NSCLC) accounts for approximately 85% of lung cancer. To treat NSCLC, STAT3 has been identified as a target with therapeutic potential. The neobavaisoflavone (NBIF) is one of the flavonoids of traditional Chinese medicine Psoralea corylifolial.

Materials and Methods: Human NSCLC cell lines, PC-9, H460, and A549, were applied to determine NBIF’s anti-proliferative effects through cell viability and colony formation detection. The effect of NBIF on cell apoptosis was determined through flow cytometry-based assay. Western blotting was used in this study to confirm the levels of P-STAT3, Bcl-2, and Bax, which are apoptotic proteins.

Results: It was observed that NBIF could decrease the cell viability and its migration and induce apoptosis in human NSCLC cell lines dose-dependently. Levels of P-STAT3, as well as the downstream signals of the STAT3 pathway, were downregulated, suggesting that the tumorsuppression effects of NBIF might be related to the inhibition of STAT3 signaling. Furthermore, NBIF could contribute to the upregulation of BAX and downregulation of BCL2.

Conclusion: NBIF might perform the anti-NSCLC efficacy as a result of the inhibition of the STAT3 pathway. Besides, our work suggests that NBIF could provide therapeutic alternatives for NSCLC.

Keywords: Neobavaisoflavone, NSCLC, STAT3, apoptosis, antitumor, pathology.

« Previous Next »
Graphical Abstract

[1]
Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2018. CA Cancer J. Clin., 2018, 68(1), 7-30.
[http://dx.doi.org/10.3322/caac.21442] [PMID: 29313949]
[2]
Zhang, H.; Yang, J.; Deng, Y.M.; Zhao, N.; Liang, J.M.; Yang, S.; Zhang, S.D.; Feng, W.N.H.Z. Multiple-line chemotherapy and tyrosine kinase inhibitor treatment in patients with advanced lung cancer. Comb. Chem. High Throughput Screen., 2019, 22(1), 27-34.
[http://dx.doi.org/10.2174/1386207322666181231122030] [PMID: 30599105]
[3]
Herbst, R.S.; Heymach, J.V.; Lippman, S.M. Lung cancer. N. Engl. J. Med., 2008, 359(13), 1367-1380.
[http://dx.doi.org/10.1056/NEJMra0802714] [PMID: 18815398]
[4]
Yin, J.; Wang, M.; Jin, C.; Qi, Q. miR-101 sensitizes A549 NSCLC cell line to CDDP by activating caspase 3-dependent apoptosis. Oncol. Lett., 2014, 7(2), 461-465.
[http://dx.doi.org/10.3892/ol.2013.1725] [PMID: 24396470]
[5]
Starakis, I.; Nikolakopoulos, A.; Mazokopakis, E.E. I S. Targeted therapies for advanced non-small cell lung cancer. Comb. Chem. High Throughput Screen., 2012, 15(8), 641-655.
[http://dx.doi.org/10.2174/138620712802650513] [PMID: 22409867]
[6]
Camidge, D.R.; Pao, W.; Sequist, L.V. Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nat. Rev. Clin. Oncol., 2014, 11(8), 473-481.
[http://dx.doi.org/10.1038/nrclinonc.2014.104] [PMID: 24981256]
[7]
Yu, H.; Lee, H.; Herrmann, A.; Buettner, R.; Jove, R. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat. Rev. Cancer, 2014, 14(11), 736-746.
[http://dx.doi.org/10.1038/nrc3818] [PMID: 25342631]
[8]
Yu, H.; Pardoll, D.; Jove, R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer, 2009, 9(11), 798-809.
[http://dx.doi.org/10.1038/nrc2734] [PMID: 19851315]
[9]
Looyenga, B.D.; Hutchings, D.; Cherni, I.; Kingsley, C.; Weiss, G.J.; Mackeigan, J.P. STAT3 is activated by JAK2 independent of key oncogenic driver mutations in non-small cell lung carcinoma. PLoS One, 2012, 7(2)e30820
[http://dx.doi.org/10.1371/journal.pone.0030820] [PMID: 22319590]
[10]
Achcar, R. O.; Cagle, P.T.; Jagirdar, J. Expression of activated and latent signal transducer and activator of transcription 3 in 303 non-small cell lung carcinomas and 44 malignant mesotheliomas: possible role for chemotherapeutic intervention. Arch. Pathol. Lab. Med., 2007, 131(9), 1350-1360.
[PMID: 17824789]
[11]
Yu, H.; Jove, R. The STATs of cancer--new molecular targets come of age. Nat. Rev. Cancer, 2004, 4(2), 97-105.
[http://dx.doi.org/10.1038/nrc1275] [PMID: 14964307]
[12]
Zhang, T.; Li, S.; Li, J.; Yin, F.; Hua, Y.; Wang, Z.; Lin, B.; Wang, H.; Zou, D.; Zhou, Z.; Xu, J.; Yi, C.; Cai, Z. Natural product pectolinarigenin inhibits osteosarcoma growth and metastasis via SHP-1-mediated STAT3 signaling inhibition. Cell Death Dis., 2016, 7(10)e2421
[http://dx.doi.org/10.1038/cddis.2016.305] [PMID: 27735939]
[13]
Bai, E.; Yang, L.; Xiang, Y.; Hu, W.; Li, C.; Lin, J.; Dai, X.; Liang, G.; Jin, R.; Zhao, C. L61H46 shows potent efficacy against human pancreatic cancer through inhibiting STAT3 pathway. Cancer Manag. Res., 2018, 10, 565-581.
[http://dx.doi.org/10.2147/CMAR.S159090] [PMID: 29606890]
[14]
Zheng, H.; Hong, H.; Zhang, L.; Cai, X.; Hu, M.; Cai, Y.; Zhou, B.; Lin, J.; Zhao, C.; Hu, W. Nifuratel, a novel STAT3 inhibitor with potent activity against human gastric cancer cells. Cancer Manag. Res., 2017, 9, 565-572.
[http://dx.doi.org/10.2147/CMAR.S146173] [PMID: 29138596]
[15]
Yang, L.; Li, J.; Xu, L.; Lin, S.; Xiang, Y.; Dai, X.; Liang, G.; Huang, X.; Zhu, J.; Zhao, C. Rhein shows potent efficacy against non-small-cell lung cancer through inhibiting the STAT3 pathway. Cancer Manag. Res., 2019, 11, 1167-1176.
[http://dx.doi.org/10.2147/CMAR.S171517] [PMID: 30774444]
[16]
Gao, S.P.; Mark, K.G.; Leslie, K.; Pao, W.; Motoi, N.; Gerald, W.L.; Travis, W.D.; Bornmann, W.; Veach, D.; Clarkson, B.; Bromberg, J.F. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J. Clin. Invest., 2007, 117(12), 3846-3856.
[http://dx.doi.org/10.1172/JCI31871] [PMID: 18060032]
[17]
Yang, L.; Lin, S.; Kang, Y.; Xiang, Y.; Xu, L.; Li, J.; Dai, X.; Liang, G.; Huang, X.; Zhao, C. Rhein sensitizes human pancreatic cancer cells to EGFR inhibitors by inhibiting STAT3 pathway. J. Exp. Clin. Cancer Res. CR (East Lansing Mich.), 2019, 38(1), 31.
[18]
Zimmer, S.; Kahl, P.; Buhl, T.M.; Steiner, S.; Wardelmann, E.; Merkelbach-Bruse, S.; Buettner, R.; Heukamp, L.C. Epidermal growth factor receptor mutations in non-small cell lung cancer influence downstream Akt, MAPK and Stat3 signaling. J. Cancer Res. Clin. Oncol., 2009, 135(5), 723-730.
[http://dx.doi.org/10.1007/s00432-008-0509-9] [PMID: 19002495]
[19]
Don, M.J.; Lin, L.C.; Chiou, W.F. Neobavaisoflavone stimulates osteogenesis via p38-mediated up-regulation of transcription factors and osteoid genes expression in MC3T3-E1 cells. Phytomedicine, 2012, 19(6), 551-561.
[http://dx.doi.org/10.1016/j.phymed.2012.01.006]
[20]
Kim, Y.J.; Choi, W.I.; Ko, H.; So, Y.; Kang, K.S.; Kim, I.; Kim, K.; Yoon, H.G.; Kim, T.J.; Choi, K.C. Neobavaisoflavone sensitizes apoptosis via the inhibition of metastasis in TRAIL-resistant human glioma U373MG cells. Life Sci., 2014, 95(2), 101-107.
[http://dx.doi.org/10.1016/j.lfs.2013.10.035] [PMID: 24231449]
[21]
Nair, R.R.; Tolentino, J.H.; Hazlehurst, L.A. Role of STAT3 in transformation and drug resistance in CML. Front. Oncol., 2012, 2, 30.
[http://dx.doi.org/10.3389/fonc.2012.00030] [PMID: 22649784]
[22]
Szliszka, E.; Skaba, D.; Czuba, Z.P.; Krol, W. Inhibition of inflammatory mediators by neobavaisoflavone in activated RAW264.7 macrophages. Molecules, 2011, 16(5), 3701-3712.
[http://dx.doi.org/10.3390/molecules16053701] [PMID: 21540797]
[23]
Szliszka, E.; Czuba, Z.P.; Sedek, L.; Paradysz, A.; Krol, W. Enhanced TRAIL-mediated apoptosis in prostate cancer cells by the bioactive compounds neobavaisoflavone and psoralidin isolated from Psoralea corylifolia. Pharmacological Reports: PR, 2011, 63(1), 139-148.
[24]
Lee, S.Y.; Kwok, S.K.; Son, H.J.; Ryu, J.G.; Kim, E.K.; Oh, H.J.; Cho, M.L.; Ju, J.H.; Park, S.H.; Kim, H.Y. IL-17-mediated Bcl-2 expression regulates survival of fibroblast-like synoviocytes in rheumatoid arthritis through STAT3 activation. Arthritis Res. Ther., 2013, 15(1), R31.
[http://dx.doi.org/10.1186/ar4179] [PMID: 23421940]
[25]
Guha, P.; Gardell, J.; Darpolor, J.; Cunetta, M.; Lima, M.; Miller, G.; Espat, N.J.; Junghans, R.P.; Katz, S.C. STAT3 inhibition induces Bax-dependent apoptosis in liver tumor myeloid-derived suppressor cells. Oncogene, 2019, 38(4), 533-548.
[http://dx.doi.org/10.1038/s41388-018-0449-z] [PMID: 30158673]
[26]
Zheng, H.; Yang, L.; Kang, Y.; Chen, M.; Lin, S.; Xiang, Y.; Li, C.; Dai, X.; Huang, X.; Liang, G.; Zhao, C. Alantolactone sensitizes human pancreatic cancer cells to EGFR inhibitors through the inhibition of STAT3 signaling. Mol. Carcinog., 2019, 58(4), 565-576.
[http://dx.doi.org/10.1002/mc.22951] [PMID: 30520143]
[27]
Jiang, R.; Jin, Z.; Liu, Z.; Sun, L.; Wang, L.; Li, K. Correlation of activated STAT3 expression with clinicopathologic features in lung adenocarcinoma and squamous cell carcinoma. Mol. Diagn. Ther., 2011, 15(6), 347-352.
[http://dx.doi.org/10.1007/BF03256470] [PMID: 22208386]
[28]
Xu, Y.H.; Lu, S. A meta-analysis of STAT3 and phospho-STAT3 expression and survival of patients with non-small-cell lung cancer. Eur. J. Surg. Oncol., 2014, 40(3), 311-317.
[http://dx.doi.org/10.1016/j.ejso.2013.11.012]
[29]
Chen, W.; Shen, X.; Xia, X.; Xu, G.; Ma, T.; Bai, X.; Liang, T. NSC 74859-mediated inhibition of STAT3 enhances the anti-proliferative activity of cetuximab in hepatocellular carcinoma. Liver Int., 2012, 32(1), 70-77.
[http://dx.doi.org/10.1111/j.1478-3231.2011.02631.x] [PMID: 22098470]

Rights & Permissions Print Cite
Article Metrics
40
4
1
1
© 2024 Bentham Science Publishers | Privacy Policy